Frontage Laboratories, Inc., a global contract research organisation (CRO), announced the acquisition of Concord Biosciences (Cleveland, USA) formerly known as Ricerca Biosciences, LLC, a preclinical CRO.
Founded in 1986, Concord Bio supports the pharmaceutical, agricultural, chemical, and animal health industries with Drug Safety, Metabolism, Bioanalytical, Residue, and Environmental Fate studies. Concord’s Drug Safety and Metabolism business offers comprehensive capabilities and conducts studies with all species commonly used in nonclinical research.
Frontage Laboratories, a full-service early-stage CRO with locations in the USA and China, has been assisting global biopharmaceutical organizations in their drug development efforts since 2001. Spanning from discovery through late-stage development, its full service offerings include Drug Metabolism and Pharmacokinetics (DMPK), bioanalysis, analytical testing, product development and full biometrics support.